

Cite this: *Chem. Commun.*, 2012, **48**, 7298–7300

www.rsc.org/chemcomm

# Novel sulphur-rich BODIPY systems that enable stepwise fluorescent O-atom turn-on and H<sub>2</sub>O<sub>2</sub> neuronal system probing<sup>†‡</sup>

Atul P. Singh,<sup>a</sup> Kang Mun Lee,<sup>a</sup> Dhiraj P. Murale,<sup>a</sup> Taehong Jun,<sup>a</sup> Hyunjeong Liew,<sup>b</sup> Yoo-Hun Suh<sup>b</sup> and David G. Churchill<sup>\*a</sup>

Received 29th February 2012, Accepted 22nd May 2012

DOI: 10.1039/c2cc33076h

**Bis-arylsulfide BODIPY systems were prepared and studied for multiple O-atom sensing (at 522 nm); 2- and 3-atom loading was optimal (50-fold, “turn on”). Neuronal studies showed greater H<sub>2</sub>O<sub>2</sub> sensitivity than 2',7'-dichlorofluorescein diacetate. The novel 1,3,6-trimethyl BODIPY formed as a biproduct under Lindsey conditions.**

Reactive oxygen species (ROS) by their name and nature are extremely unstable. High levels can cause biological damage implicated in cancer, neurodegeneration, diabetes, *etc.* Molecular level effects such as extensive lipid peroxidation, protein oxidation, and mitochondrial DNA mutation arise from excess biological hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), superoxide (O<sub>2</sub><sup>−</sup>), hydroxyl (•OH), singlet oxygen, and lipid hydroperoxide concentrations. Selective and sensitive detection and quantification of such species by luminescent molecules may allow for a better understanding of the intricacies of biological processes.

The rational synthesis of well-defined systems paves the way for novel synthetic probes with improved and varying functions.<sup>1–5</sup> Oxidative transformations in synthetic systems have involved boronate, quinone, olefin, reduced moieties, and lanthanide-based systems, and the photomechanisms of PET, FRET, phosphorescence *etc.*<sup>1</sup>

BODIPY (4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene) species are resilient, easily derivatizable and have been prepared for a host of optical applications.<sup>2</sup> They are commonly synthesized by the straight-forward Lindsey method.<sup>4</sup> Sulphide- or thienyl-functionalized BODIPY platforms for fluorescent ROS detection are few.<sup>5</sup> Direct *chemical* sulphide oxidation accesses valence states 4 and 6. The oxidation of Met in proteins might access, *e.g.*, neurodegenerative disease pathways. Dyes with *multiple* inputting are also important targets.<sup>3</sup> Herein, we report a full study of novel and fully characterized 4-tolyl sulphide-containing thienyl BODIPY species that allow for ROS sensing.

Synthetically, 3-thiophene carboxaldehyde was selected as a starting aldehyde to enable sequential asymmetric sulphide incorporation. First, *N*-bromo succinimide (NBS) effected dibromination of the thiophene carboxaldehyde (DMF). Arylsulphide intermediates 2,5-bis(4-tolylsulfide)- (**1**) and 5-bromo-2-(4-tolylsulfide)-3-thiophene carboxaldehyde (**1a**) were prepared efficiently by an adapted CuI/BtH-catalyzed coupling of 2,5-dibromothiophene carboxaldehyde with *p*-toluenethiol (see ESI<sup>†</sup>).<sup>6</sup> The BODIPY derivatives **2** and **2a** were then conveniently prepared *via* the Lindsey method (Scheme 1);<sup>3</sup> authentication was made by <sup>1</sup>H, <sup>13</sup>C, and <sup>11</sup>B NMR spectroscopy, and high-resolution ES-mass spectrometry (ESI<sup>†</sup>). UV-PL data of **2** ( $\Phi_F = 0.01$ ), and **2a** ( $\Phi_F = 0.06$ ) were obtained (Fig. 1 and ESI<sup>†</sup>). Formal incorporation of thiol groups greatly limits BODIPY fluorescence; compound **2**, because of its lower  $\Phi_F$  value (“turned off”), was used further in potential ROS “turn on” assays.


Compound **2** was assayed by ROS-type species to determine the extent of sulphur oxidation (Fig. 2) as determined by fluorescence changes (Fig. 3). *m*-CPBA (1.0 × 10<sup>−4</sup> M) in MeCN:H<sub>2</sub>O (70:30 by vol) with **2** (1.0 × 10<sup>−6</sup> M) gave a “turn-on” response (2 h: 11-fold; 15 h: 50-fold) at 522 nm (Fig. 1 and ESI<sup>†</sup>). Interestingly, **2** was unresponsive with H<sub>2</sub>O<sub>2</sub>, NaOCl, KO<sub>2</sub>, •OH, •O•Bu, and <sup>t</sup>BuOOH under analogous conditions. Interestingly, this reactivity pattern is different

<sup>a</sup> Molecular Logic Gate Laboratory, Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), 373-1 Guseong-dong, Yuseong-gu, Daejeon 305-701, Republic of Korea. E-mail: dchurchill@kaist.ac.kr


<sup>b</sup> Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, MRC, Seoul National University, Seoul 110-799, Republic of Korea

<sup>†</sup> Electronic supplementary information (ESI) available: Experimental details, in-line spectral data, reproductions of NMR spectra, HR MS spectra, Crystallographic data, structural bond lengths and angles, *etc.* CCDC 860722, 869054 and 869055. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c2cc33076h


<sup>‡</sup> Crystallographic Data: Compound **7** (CCDC 860722): C<sub>31</sub>H<sub>29</sub>BF<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S<sub>3</sub>, F.W.: 622.55. Monoclinic, *C*2/*c*, *Z* = 8, *a* = 37.899(9) Å, *b* = 7.743(2) Å, *c* = 25.029(7) Å,  $\beta$  = 122.015(11)°, *V* = 6227(3) Å<sup>3</sup>, *T* = 296(2)K, No. reflections = 28247, No. independent reflections = 7373 [R(int) = 0.1082], *R*<sub>1</sub> = 0.0845, *wR*<sub>2</sub> = 0.2158,  $\mu$ /mm<sup>−1</sup> = 0.285, Largest diff. peak and hole = 0.793 and 0.553 e<sup>−</sup>/Å<sup>−3</sup>. Compound **8** (CCDC 869055): C<sub>31</sub>H<sub>29</sub>BF<sub>2</sub>N<sub>2</sub>O<sub>4</sub>S<sub>3</sub>, F.W. = 638.55, monoclinic, *C*2/*c*, *Z* = 8, *a* = 38.241(9) Å, *b* = 7.6428(18) Å, *c* = 25.192(7) Å,  $\beta$  = 121.40(2)°, *V* = 6285(3) Å<sup>3</sup>, *T* = 296(2)K, No. of reflections = 27214, No. of independent reflections = 4422 [R(int) = 0.0713], *R*<sub>1</sub> = 0.0508, *wR*<sub>2</sub> = 0.1466,  $\mu$ /mm<sup>−1</sup> = 0.286, Largest diff. peak and hole = 0.331 and −0.264 e<sup>−</sup>/Å<sup>−3</sup>. Compound **9** (CCDC 869054): C<sub>12</sub>H<sub>13</sub>BIF<sub>2</sub>N<sub>2</sub>, F.W. = 234.05, Monoclinic, *P*2<sub>1</sub>/*c*, *Z* = 4, *a* = 6.350(3) Å, *b* = 13.032(7) Å, *c* = 14.253(7) Å,  $\beta$  = 94.75(2)°, *V* = 1175.4(10) Å<sup>3</sup>, *T* = 296(2)K, No. of reflections = 16333, No. of independent reflections = 4133 [R(int) = 0.0857], *R*<sub>1</sub> = 0.0992, *wR*<sub>2</sub> = 0.2003,  $\mu$ /mm<sup>−1</sup> = 0.100, Largest diff. peak and hole = 0.287 and −0.178 e<sup>−</sup>/Å<sup>−3</sup>.




**Scheme 1** Synthesis of the mono- and dithiol-derivatized aldehydes (**1** and **1a**) from 3-thiophene carboxaldehyde, and BODIPY compounds **2** and **2a** (ESI†).



**Fig. 1** (left) Cuvette emission spectra of compound **2** (1 × 10<sup>-6</sup> M) and “turn-on” response (50-fold, 522 nm) with *m*-CPBA (100 eq) in acetonitrile/water (70:30) after 2 and 15 h ( $\lambda_{\text{exc}} = \lambda_{\text{abs}} = 506$  nm) (ESI†). (right) Fluorescence microscopy images of cultured neuroblastoma for **2** at 100 μmol with H<sub>2</sub>O<sub>2</sub> after incubation (2 h, 37 °C;  $\lambda_{\text{exc}} = 543$  nm,  $\lambda_{\text{em}} = 592$  nm) (see ESI†).



**Fig. 2** BODIPY crystal structures of (left) the trioxidized **7**, an arylsulfoxide–arylsulfone and (right) the tetraoxidized **8**, a bis-arylsulfone (CCDC #'s: 860722 & 869055, respectively). Hydrogen atoms are omitted for clarity, percentage of thermal ellipsoids = 30%.




**Fig. 3** (left) Selectivity of **2** for *m*-CPBA, and (right) comparison of  $\Phi_F$  values for compounds **2**, **6**, **7**, and **8** (522 nm).

from that reported for the related 2-SMe-substitution, selective for NaOCl.<sup>5</sup>


Next, cellular fluorescence microscopy studies with SH-SY5Y neuroblastoma were carried out on **2** and the commercial 2',7'-dichlorofluorescein diacetate (DCFDA) for comparison (Fig. 1 and ESI†); **2** compartmentalized in the cytosol and was found to be sensitive to endogenous H<sub>2</sub>O<sub>2</sub>, in fact more so than the fluorescein species was (30 min).<sup>7</sup> Various conditions were measured (ESI†). Furthermore, compound **2** was found non-neurotoxic at 100 μM, as determined by LDH assaying (ESI†). The calculated *c* log *P* value for **2** (2.75) indicates promise for possible blood-brain barrier penetrability.

Next, to consider how the emission signal and molecular geometry are attenuated upon stepwise [O]-atom incorporation, we synthesised, isolated and characterized compounds **6–8**, the discrete proposed BODIPY products of oxidation (Scheme 2, Fig. 2, ESI†). Aldehyde **1** was oxidized (*m*-CPBA) and its products were isolated and characterized for convenient BODIPY (**6–8**) preparation (ESI†). <sup>1</sup>H NMR spectra show inequivalent 1,3,5,7-position methyls and 2,6-position methines for **6** and **7** (ESI†). These compounds are also highly fluorescent as predicted ( $\Phi_F = \sim 1.00$ ). To confirm that **6–8** are genuine products of *m*-CPBA oxidation, **2** was treated separately with excess *m*-CPBA (CH<sub>2</sub>Cl<sub>2</sub>, 0 °C); <sup>1</sup>H NMR spectral analysis revealed three major products assigned to **6–8**.

Structural data was also obtained and can be brought into line with spectroscopic data. Crystal structures of **7** and **8** confirm the expected BODIPY species with the trioxidized arylsulfoxide–arylsulfone and tetraoxidized bis-arylsulfone moieties, respectively (Fig. 2). The crystal structure of **7** reveals one sulfoxide and one sulfone (Fig. 2). In contrast, that for compound **8** reveals two sulfones and is C<sub>s</sub>-symmetric by <sup>1</sup>H NMR spectroscopy, suggesting rapid arylsulfone motion on the NMR time-scale (RT, CDCl<sub>3</sub>). The final oxidation site is at the proximal sulfide. The  $\Phi_F$  value of **8** (~0.59) is 40% lower than that of **7**. From the emission data, importantly, the



**Scheme 2** Preparation and characterization of BODIPY oxidation products of **2** with *p*-chloranil, and the simple BODIPY by-product species **9**.



**Fig. 4** Crystal structure of **9** (CCDC #: 869054). Hydrogen atoms are omitted for clarity, percentage of thermal ellipsoids = 30%.

first-oxygenation of the proximal sulphur allows for a  $\sim 100$ -fold increase in  $\Phi_F$  value; upon oxidation, the entire 8-aryl moiety gains steric hindrance, rotational inhibition allows the fluorophore to possess higher fluorescence.<sup>3,8</sup> The sulfone in **8**, involves a combined electronic and steric attenuation of fluorescence (ESI<sup>+</sup>); structurally, the fourth [O] must direct itself toward the BODIPY fluorophore (Fig. 2). Red shifting for the series (**6** < **7** < **8**:  $\lambda_{\text{ABS}}$ : 509 < 512 < 515;  $\lambda_{\text{EM}}$ : 523 < 524 < 527) suggests a growing heteroatomic influence of the thienyl donor moiety to the BODIPY acceptor. Oxidation at the distal sulfide imparts a subtle photophysical effect not underscored here. Compound **2** was also assayed with potentially interfering metal cations (50 equiv); no fluorescence perturbations were found, except for minor quenching effect for  $\text{Cu}^{2+}$  ( $-20\%$ ) and  $\text{Hg}^{2+}$  ( $-15\%$ ). For  $\text{Hg}^{2+}$ , very slight bathochromic shifting for **6** (3 nm) and **7** (4 nm), and hypsochromic shifting for **8** (2 nm) was found in MeCN (ESI<sup>+</sup>).  $c \log P$  values were calculated and found to decrease: **6**: 1.62 > **7**: 1.06 > **8**: 0.498, suggesting worsening BBB penetrability with more O-loading.

Surprisingly, the reaction of **5** with 2,4-dimethyl pyrrole gave the novel and highly fluorescent 1,3,6-trimethyl-4,4-difluoroboradiazaindacene ( $\Phi_F = 0.98$ ) as a side product in 9.9% yield ( $R_f$  0.70,  $\text{CH}_2\text{Cl}_2$ ). High resolution-MS confirmed a low MW molecule (257.1038 (cal.), 257.1033 (exp.)). The structure by solution  $^1\text{H}$  NMR spectroscopy reveals four aromatic singlets ( $\delta$  7.46, 7.06, 6.68, 6.09) and three aliphatic singlets ( $\delta$  2.54, 2.23, 2.10). The asymmetric nature of **9**, where two methyls exist on one side and a single methyl is present on the opposite side of the molecule, is supported structurally as well (Fig. 4). Interestingly, in a deviation from the known Lindsey reaction, the formation of **9** requires **5**, but not TFA. Remarkably, no product formation was detected in the presence of **4**, suggesting the subtlety of proximal sulfone/sulfoxide sterics in product formation in which the 4-methyl carbon of the first 2,4-dimethylpyrrole bonds to the ring 5-carbon of the second 2,4-dimethylpyrrole via oxidation/condensation.

Herein, we report the preparation and characterization of various closely-related sulphur-containing BODIPY species for ROS sensing. Stepwise chemical *S*-oxidations effected by *m*-CPBA or  $\text{H}_2\text{O}_2$  can greatly enhance molecular fluorescence. Specifically, oxygen atom loading gives respective sulfoxide/sulfone groups: enhancement is found with 3[O]-atom loading (**7**); a diminished capacity is found for 4[O]-atom loading (**8**). The greatest emission changes are seen when the sulfide that is

proximal to the chromophore is oxidized; cuvette optical data show selective “turn-on” behavior (50-fold) with *m*-CPBA (over  $\text{H}_2\text{O}_2$ , NaOCl,  $\text{KO}_2$ ,  $\cdot\text{OH}$ ,  $\cdot\text{O}'\text{Bu}$ , and  $\text{BuOOH}$ ) in 30+ % water. Neuroblastoma cellular trials with **2** show responses for  $\text{H}_2\text{O}_2$ . Structural data support the asymmetric findings gleaned from NMR spectral data. Geometric impositions give rise to increased molecular fluorescence to a point. Lastly, bis-arylsulfone aldehyde **5** facilitates the unexpected formation of a simple, asymmetric trimethyl BODIPY species (1,3,6-trimethyl-4,4-difluoroboradiazaindacene) ( $\Phi_F = \sim 1.00$ ). We hope to fine-tune the concept of stepwise oxidation for neurodegenerative disease research through future studies.

The Molecular Logic Gate Laboratory operated by D.G.C. acknowledges research support from the National Research Foundation (NRF) (Grant # 2009-0070330 & 2010-0013660, 2011-0017280). Mr Hack Soo Shin and Prof. Youngkyu Do are acknowledged, respectively, for facilitating the acquisition of NMR spectroscopic and crystallographic data. The research support staff at KAIST facilitated the acquisition of our MS data. We thank Deposition Coordinator Kamila Nowakowska (CCDC).

## References

- 1 Refer to these general reviews on ROS sensing: (a) B. C. Dickinson and C. J. Chang, *Nat. Chem. Biol.*, 2011, **7**, 504; (b) M. Schaeferling, D. B. M. Groegel and S. Schreml, *Microchim. Acta*, 2011, **174**, 1–18; (c) B. C. Dickinson, D. Srikun and C. J. Chang, *Curr. Opin. Chem. Biol.*, 2010, **14**, 50; (d) C. C. Winterbourn, *Nat. Chem. Biol.*, 2008, **4**, 278; (e) B. Halliwell and J. M. C. Gutteridge, *Free Radicals in Biology and Medicine*, Oxford University Press, Oxford, 4th edn, 2007; (f) P. Wardman, *Free Radical Biol. Med.*, 2007, **43**, 995; (g) N. Soh, *Anal. Bioanal. Chem.*, 2006, **386**, 532.
- 2 For BODIPY reviews, see: (a) A. Loudet and K. Burgess, *Chem. Rev.*, 2007, **107**, 4891. For hydrogen peroxide see: (b) A. C. Benniston, G. Copley, K. J. Elliott, R. W. Harrington and W. Clegg, *Eur. J. Org. Chem.*, 2008, 2705; (c) G. M. J. Makrigrigoris, *J. Biochem. Biophys. Methods*, 1997, **35**, 23.
- 3 *Multi input probes*: (a) H. Maeda, K. Yamamoto, Y. Nomura, I. Kohno, L. Hafsi, N. Ueda, S. Yoshida, M. Fukada, Y. Fukuyasu, Y. Yamauchi and N. Itoh, *J. Am. Chem. Soc.*, 2005, **127**, 68; (b) E. W. Miller, A. E. Albers, A. Pralle, E. Y. Isacoff and C. J. Chang, *J. Am. Chem. Soc.*, 2005, **127**, 16652; (c) K. Xu, B. Tang, H. Huang, G. Yang, Z. Chen, P. Li and L. An, *Chem. Commun.*, 2005, 5974.
- 4 (a) C. Bruckner, V. Karunaratne, S. J. Rettig and D. Dolphin, *Can. J. Chem.*, 1996, **74**, 2182–2193; (b) R. W. Wagner and J. S. Lindsey, *Pure Appl. Chem.*, 1996, **68**, 1373–1380; (c) C. H. Lee and J. S. Lindsey, *Tetrahedron*, 1994, **50**, 11427–11440.
- 5 (a) T.-I. Kim, S. Park, Y. Choi and Y. Kim, *Chem.-Asian J.*, 2011, **6**, 1358; (b) S. H. Choi, K. Kim, J. Jeon, B. Meka, D. Bucella, K. Pang, S. Khatua, J. Lee and D. G. Churchill, *Inorg. Chem.*, 2008, **47**, 11071; (c) H. Rohr, C. Trieflinger, K. Rurack and J. Daub, *Chem.-Eur. J.*, 2006, **12**, 689.
- 6 (a) A. K. Verma, J. Singh and R. Chaudhary, *Tetrahedron Lett.*, 2007, **48**, 7199; (b) Z. Duan, S. Ranjit and X. Liu, *Org. Lett.*, 2010, **12**, 2430.
- 7 (a) S. Lemcke, C. Honnscheidt, G. Waschatko, A. Bopp, D. Lutjohann, N. Bertram and K. Gehrig-Burger, *Molecular and Cellular Endocrinology*, 2010, **314**, 31; (b) S. Arttamangkul, V. Alvarez-Maubecin, G. Thomas, J. T. Williams and D. K. Grandy, *Mol. Pharmacol.*, 2000, **58**, 1570.
- 8 H. L. Kee, C. Kirmaier, L. H. Yu, P. Thamyongkit, W. J. Youngblood, M. E. Calder, L. Ramos, B. C. Noll, D. F. Bocian, W. R. Scheidt, R. R. Birge, J. S. Lindsey and D. Holten, *J. Phys. Chem. B*, 2005, **109**, 20433.